Multiple Myeloma Treatment
Clinical activity is centered on multiple myeloma across newly diagnosed, relapsed, and high-risk settings, including patients with extramedullary disease and those eligible or ineligible for autologous stem cell transplantation.
- Newly diagnosed multiple myeloma
- Relapsed multiple myeloma
- Transplant-eligible and transplant-ineligible disease
- Extramedullary involvement
The research portfolio also includes younger patients with transplant-related treatment pathways and maintenance-focused approaches after initial disease control.
Plasma Cell Disorder Research
Work extends to high-risk smoldering multiple myeloma and disease monitoring in settings where early intervention and response assessment are central to care.
- High-risk smoldering multiple myeloma
- Minimal residual disease
- Complete response assessment
- Progression-free survival
Research interests include deeper remission states and sustained disease control in patients at increased risk of progression.
AL Amyloidosis and Related Disorders
The sponsor is also active in immunoglobulin light-chain (AL) amyloidosis, including relapsed or refractory disease and previously treated patients requiring hematologic response improvement.
- Immunoglobulin light-chain (AL) amyloidosis
- Relapsed or refractory AL amyloidosis
- Hematologic response
- Previously treated disease
This area reflects interest in systemic plasma cell disorders with overlapping therapeutic strategies and response endpoints.
Novel Immunotherapy and Cellular Treatment Pathways
Several trials focus on immunotherapy and cellular therapy approaches, including combinations built around bispecific antibodies and CAR-T-related treatment sequences in myeloma.
- Bispecific antibody-based treatment
- CAR-T therapy
- Combination immunotherapy
- Maintenance treatment strategies
These studies are linked to earlier consolidation, sustained remission, and deeper measurable disease clearance.
Response Monitoring in Hematologic Malignancy
Research activity includes detailed minimal residual disease assessment using sensitive molecular and protein-based monitoring in multiple myeloma and related plasma cell disorders.
- Next-generation sequencing
- Molecular response monitoring
- Serologic disease tracking
- Sustained MRD negativity
This emphasis supports treatment evaluation in consolidation and maintenance settings across several myeloma subgroups.
